Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONS-3010 versus US and EU Humira in healthy adults
NL-OMON41013Active, not recruiting
- Sponsor
- Outlook Therapeutics
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of adalimumab and ONS-3010 in autoimmune disease (3 arms), sponsored by Outlook Therapeutics. Primary endpoints: AUC0-inf and Cmax. Started Jul 2014; status: active, not recruiting.
02
Drugs
adalimumabONS-3010
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON41013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41013.